Human immunodeficiency virus type-1 (HIV) remains a near-inexorable cause of neurological and behavioral disease (NeuroAIDS) despite the prolonged survival of many HIV-infected (HIV+) individuals associated with use of highly active antiretroviral therapy (HAART). The failure of current HAART regimens to eliminate HIV from the CNS has led to the development of a protected viral reservoir, new forms of HIV associated neurocognitive disorder (HAND), and increasing numbers of age-related neurological disorders in older HIV+ persons. In order to address these evolving issues, investigators require well-characterized human CNS tissues and fluids from well-characterized cohorts. Thus, the human tissues, fluids, and data provided by the National Neurological AIDS Bank (NNAB) and National NeuroAIDS Tissue Consortium (NNTC), remain essential for investigators to perform studies that will benefit HIV+ patients. To date, the NNAB has successfully recruited 719 participants of diverse racial, ethnic, linguistic, and educational backgrounds and both genders. We follow a living cohort of 184 participants, and we have performed 228 autopsies, of which 86% of descendants had pre-mortem study data. We have supplied 216 requests for tissues and data, and we have generated numerous independently funded research projects at UCLA that enhance our resources and further the science of NeuroAIDS. We actively collaborate with the other NNTC clinical sites and the NNTC Data Coordinating Committee (DCC) to maintain an up-to-date central database and specimen inventory and to fulfill requests for tissues, fluids, and data. Since the advent of the NNTC initiative, our participants have lived longer than was anticipated. This has engendered new problems and has forced us to be scientifically nimble and to rapidly adjust to the changing face of the HIV pandemic. The NNAB, adapting in turn, has successful research projects and collaborations that interact with the Bank and advance the very field of NeuroAIDS. We look forward to continuing our work with our colleagues at the other clinical sites, the DCC, and the NIH, on this important and for many, life- changing project.

Public Health Relevance

To develop treatments for NeuroAIDS, researchers require a continuous, reliable source of well- characterized human specimens and data. The National Neurological AIDS Bank (NNAB) is in a unique position to meet the. needs of NeuroAIDS researchers. Over the past 5 years we have been among the top contributors of well-characterized human tissues, fluids and data to the National NeuroAIDS Tissue Consortium (NNTC) and will continue this trend in the future.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
1U24MH100929-01
Application #
8539923
Study Section
Special Emphasis Panel (ZMH1-ERB-C (04))
Program Officer
Rausch, Dianne M
Project Start
2013-05-10
Project End
2018-04-30
Budget Start
2013-05-10
Budget End
2014-04-30
Support Year
1
Fiscal Year
2013
Total Cost
$1,182,485
Indirect Cost
$395,162
Name
University of California Los Angeles
Department
Neurology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Gill, Alexander J; Garza, Rolando; Ambegaokar, Surendra S et al. (2018) Heme oxygenase-1 promoter region (GT)n polymorphism associates with increased neuroimmune activation and risk for encephalitis in HIV infection. J Neuroinflammation 15:70
Guha, Debjani; Mukerji, Shibani S; Chettimada, Sukrutha et al. (2018) CSF extracellular vesicles and neurofilament light protein as biomarkers of CNS injury in HIV-infected patients on antiretroviral therapy. AIDS :
Anderson, Ariana E; Jones, Jacob D; Thaler, Nicholas S et al. (2018) Intraindividual variability in neuropsychological performance predicts cognitive decline and death in HIV. Neuropsychology 32:966-972
Premeaux, Thomas A; D'Antoni, Michelle L; Abdel-Mohsen, Mohamed et al. (2018) Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol :
Chettimada, Sukrutha; Lorenz, David R; Misra, Vikas et al. (2018) Exosome markers associated with immune activation and oxidative stress in HIV patients on antiretroviral therapy. Sci Rep 8:7227
Quach, Austin; Horvath, Steve; Nemanim, Natasha et al. (2018) No reliable gene expression biomarkers of current or impending neurocognitive impairment in peripheral blood monocytes of persons living with HIV. J Neurovirol 24:350-361
Lamers, Susanna L; Fogel, Gary B; Liu, Enoch S et al. (2018) Brain-specific HIV Nef identified in multiple patients with neurological disease. J Neurovirol 24:1-15
Rose, Rebecca; Nolan, David J; Maidji, Ekaterina et al. (2018) Eradication of HIV from Tissue Reservoirs: Challenges for the Cure. AIDS Res Hum Retroviruses 34:3-8
Nolan, David J; Rose, Rebecca; Rodriguez, Patricia H et al. (2018) The Spleen Is an HIV-1 Sanctuary During Combined Antiretroviral Therapy. AIDS Res Hum Retroviruses 34:123-125
Soontornniyomkij, Virawudh; Umlauf, Anya; Soontornniyomkij, Benchawanna et al. (2018) Association of antiretroviral therapy with brain aging changes among HIV-infected adults. AIDS 32:2005-2015

Showing the most recent 10 out of 118 publications